David Chadbourne, MD
Urology · Seneca, SCNPI 1740277011
Payments from drug & device makers
Across 49 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$200
- Astellas Pharma US Inc$133
- AstraZeneca$87
- Coloplast$82
- Biogen$59
- Merck$41
- plus $367 from 20 others
What the payments were for
- Speaking & faculty fees$222%
- Food & beverage$77780%
- Education$17118%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $200 |
| Astellas Pharma US Inc | 3 | $133 |
| AstraZeneca(2 entities) | 5 | $87 |
| Coloplast | 3 | $82 |
| Biogen | 4 | $59 |
| Merck | 3 | $41 |
| CSL Behring | 2 | $35 |
| UCB, Inc. | 1 | $29 |
| Adamas Pharmaceuticals, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Calyxo, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| AbbVie | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $4 |
How this compares
$969 in reported general payments places this provider in the 25th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $187 |
| Tamsulosin Hcl | 18 | $162 |
Paid to pharmacies, not to this prescriber.
Other urology in Seneca
- Neal ShoreMyrtle Beach$63.3M
- Sandip PrasadCharleston$2.4M
- Stephen SavageCharleston$2.1M
- Justin EllettN Charleston$727K
- Thomas KeaneCharleston$281K
- Kimberly BurgessGreenville$271K
- Manish PatelElgin$213K
- William LowranceGreenville$201K
- Joseph BusbyGreenville$185K
- Abhishek SrivastavaMyrtle Beach$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.